Centene price target lowered to $35 from $42 at Truist

Truist lowered the firm’s price target on Centene (CNC) to $35 from $42 but keeps a Buy rating on the shares after its Q2 results. The firm notes that while the environment around cost trends remain difficult and carries near/intermediate term uncertainties, the company’s Prescription Drug Plan and Medicare Advantage lines are performing better, the analyst tells investors in a research note.